An update on the recent literature on sickle cell bone disease

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 6, 2013, Pages 539-546

  Osunkwo, Ifeyinwa ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone disease; Chronic pain; Osteonecrosis; Osteopenia; Osteoporosis; Sickle; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ANNEXIN; C REACTIVE PROTEIN; HYDROXYUREA; LIPOCORTIN 2; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ACUTE CHEST SYNDROME; AVASCULAR NECROSIS; BONE DENSITY; BONE DISEASE; BONE SCINTISCANNING; BONE TURNOVER; CEMENTLESS PROSTHESIS; CEREBROVASCULAR ACCIDENT; CHRONIC PAIN; COST EFFECTIVENESS ANALYSIS; CRANIOFACIAL MALFORMATION; DNA POLYMORPHISM; DRUG MEGADOSE; FRACTURE; GENETIC POLYMORPHISM; HUMAN; LEUKOCYTE COUNT; MULTIPLE ORGAN FAILURE; MUSCULOSKELETAL PAIN; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOMYELITIS; OSTEOPENIA; OSTEOPOROSIS; POSTOPERATIVE INFECTION; PROSTHESIS INFECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SICKLE CELL; SICKLE CELL BONE DISEASE; TOOTH PULP DISEASE; TOTAL HIP PROSTHESIS; VEIN THROMBOSIS; VERTEBRA MALFORMATION; VITAMIN D DEFICIENCY;

AGING; ANEMIA, SICKLE CELL; ANNEXIN A1; BONE DISEASES, METABOLIC; FEMALE; HUMANS; LIFE EXPECTANCY; MALE; OSTEONECROSIS; OSTEOPOROSIS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; VITAMIN D DEFICIENCY;

EID: 84890115995     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/01.med.0000436192.25846.0b     Document Type: Review

References (63)

1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639-1644.
2. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999; 340:1021-1030.
3. Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999-2009). Pediatr Blood Cancer 2013; 60:1482-1486.
4. Ballas SK. Pain management of sickle cell disease. Hematol Oncol Clin North Am 2005; 19:785-802.
5. Da Silva Junior GB, Daher Ede F, da Rocha FA. Osteoarticular involvement in sickle cell disease. Rev Bras Hematol Hemoter 2012; 34:156-164. This succinct review of the various osteoarticular complications of sickle cell disease includes a summary and visual schema of the proposed pathophysiologic mechanisms responsible for sickle cell bone disease.
6. Almeida A, Roberts I. Bone involvement in sickle cell disease. Br J Haematol 2005; 129:482-490.
7. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 2004; 11:129-151.
8. Ballas SK, Kesen MR, Goldberg MF, et al. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. Sci World J 2012; 2012:949535. The section on muscular and skeletal and skin complications in this article represents a comprehensive update on the epidemiology and clinical management of musculoskeletal complications in SCD, obtained from a review of the literature and a survey of the clinical experts in the field.
9. Paszty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 1997; 278:876-878.
10. Braun T, Schett G. Pathways for bone loss in inflammatory disease. Curr Osteoporos Rep 2012; 10:101-108. This article summarizes the new data on the inflammatory bone loss and the emerging field of osteoimmunology that may be relevant to the pathogenesis of sickle cell bone disease.
11. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006; 116:1186-1194.
12. Cenci S, Weitzmann MN, Roggia C, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000; 106:1229-1237.
13. Chang J, Wang Z, Tang E, et al. Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med 2009; 15:682-689.
14. Baldanzi G, Traina F, Marques Neto JF, et al. Low bone mass density is associated with hemolysis in Brazilian patients with sickle cell disease. Clinics (Sao Paulo) 2011; 66:801-805.
15. Miller RG, Segal JB, Ashar BH, et al. High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. Am J Hematol 2006; 81:236-241.
16. Sadat-Ali M, Al-Elq AH, Sultan O, et al. Low bone mass due to sickle cell anemia: is it becoming a real issue?. West Afr J Med 2008; 27:218-223.
17. Sadat-Ali M, Al Elq AH. Sickle cell anaemia: is it a cause for secondary osteoporosis?. West Afr J Med 2007; 26:134-137.
18. Sadat-Ali M, Al-Elq A, Sultan O, Al-Turki H. Secondary osteoporosis due to sickle cell anemia: do sex steroids play a role?. Indian J Med Sci 2008; 62:193-198.
19. Sadat-Ali M, Sultan O, Al-Turki H, Alelq A. Does high serum iron level induce low bone mass in sickle cell anemia?. Biometals 2011; 24:19-22.
20. Lal A, Fung E, Vichinsky E. Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer 2006; 47:901-906.
21. Gupta R, Marouf R, Adekile A. Pattern of bone mineral density in sickle cell disease patients with the high-Hb F phenotype. Acta Haematol 2010; 123:64-70.
22. Sarrai M, Duroseau H, D'Augustine J, et al. Bone mass density in adults with sickle cell disease. Br J Haematol 2007; 136:666-672.
23. Osunkwo I, Hodgman EI, Cherry K, et al. Vitamin D deficiency and chronic pain in sickle cell disease. Br J Haematol 2011; 153:538-540.
24. Osunkwo I, Ziegler TR, Alvarez J, et al. High dose vitamin D therapy for chronic pain in children and adolescents with sickle cell disease: results of a randomized double blind pilot study. Br J Haematol 2012; 159:211-215. This is the first study to investigate the role of vitamin D supplementation on clinical experience of daily pain in sickle cell disease.
25. Elshal MF, Bernawi AE, Al-Ghamdy MA, Jalal JA. The association of bone mineral density and parathyroid hormone with serum magnesium in adult patients with sickle-cell anaemia. Arch Med Sci 2012; 8:270-276. This article investigates the role of magnesium in bone turnover, identifying a group of patients with sickle cell disease with low magnesium who also had significantly lower bone mineral density than those with normal magnesium.
26. Fung EB, Harmatz PR, Milet M, et al. Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone 2008; 43:162-168.
27. Lips P. Epidemiology and predictors of fractures associated with osteoporosis. Am J Med 1997; 103:3S-8S; discussion S-11S.
28. Straube S, Moore RA, Derry S, MacQuay H. Vitamin D and chronic pain. Pain 2009; 141:10-13.
29. Holick M. Vitamin D deficiency. N Engl J Med 2007; 357:266-281.
30. Osunkwo I. Complete resolution of sickle cell chronic pain with high dose vitamin D therapy: a case report and review of the literature. J Pediatr Hematol Oncol 2011; 33:549-551.
31. Sadat-Ali M, Al-Elq A, Al-Turki H, et al. Vitamin D level among patients with sickle cell anemia and its influence on bone mass. Am J Hematol 2011; 86:506-507.
32. Goodman B, Artz N, Radford B, Chen I. Prevalence of vitamin D deficiency in adults with sickle cell disease. J Natl Med Assoc 2010; 102:332-335.
33. Rovner A, Stallings V, Kawchak D, et al. High risk of vitamin D deficiency in children with sickle cell disease. J Am Diet Assoc 2008; 108:1512-1516.
34. Garrido C, Cela E, Belendez C, et al. Status of vitamin D in children with sickle cell disease living in Madrid, Spain. Eur J Pediatr 2012; 171:1793-1798. This article describes the epidemiology of vitamin D deficiency in Madrid, Spain, but more importantly investigates children under the age of 12 months of age with a lower mean age than other published studies in the field.
35. Arlet JB, Courbebaisse M, Chatellier G, et al. Relationship between vitamin D deficiency and bone fragility in sickle cell disease: a cohort study of 56 adults. Bone 2013; 52:206-211. This study supports the body of literature on extremely high prevalence of vitamin D deficiency in sickle cell disease in association with increased bone turnover and rates of fractures and bone fragility.
36. Adams-Graves P, Daniels AB, Womack CR, Freire AX. Bone mineral density patterns in vitamin D deficient African American men with sickle cell disease. Am J Med Sci 2013. [Epub ahead of print]. This article demonstrates high rates of low bone mineral density among men with sickle cell disease who are vitamin-D deficient-a reminder that low bone density screening should include at-risk men as well as women.
37. Jackson TC, Krauss MJ, Debaun MR, et al. Vitamin D deficiency and comorbidities in children with sickle cell anemia. Pediatr Hematol Oncol 2012; 29:261-266. The authors attempted to evaluate the association between vitamin D status and acute vaso-occlusive pain and ACS in sickle cell disease. Although they found no association with these acute complications, they noted importantly that vitamin D status was a predictor of lung function measured by FEV1.
38. Schwalfenberg G. Improvement of chronic back pain or failed back surgery with vitamin D repletion: a case series. J Am Board Fam Med 2009; 22:69-74.
39. Ohara DG, Ruas G, Castro SS, et al. Musculoskeletal pain, profile and quality of life of individuals with sickle cell disease. Rev Bras Fisioter 2012; 16:431-438. This study highlights the public health consequences of daily chronic pain in SCD as significantly impacting the quality of life in the domains of physical functioning, mental and emotional wellbeing.
40. Taylor LE, Stotts NA, Humphreys J, et al. A review of the literature on the multiple dimensions of chronic pain in adults with sickle cell disease. J Pain Symptom Manage 2010; 40:416-435.
41. Anie KA, Green J. Psychological therapies for sickle cell disease and pain. Cochrane Database Syst Rev 2012; 2:CD001916. This comprehensive review of the use of psychological therapies in sickle cell disease demonstrates limited evidence to their efficacy and a significant need for adequately powered randomized studies to quantify the benefit of specific interventions.
42. Javed F, Correa FO, Nooh N, et al. Orofacial manifestations in patients with sickle cell disease. Am J Med Sci 2013; 345:234-237. This review of the literature on orofacial complications of sickle cell disease highlights the importance of maintaining adequate oral health by regular screening to prevent potential clinically significant complications and emergencies.
43. Elias EJ, Liao JH, Jara H, et al. Quantitative MRI analysis of craniofacial bone marrow in patients with sickle cell disease. AJNR Am J Neuroradiol 2013; 34:622-627. The results of this study suggests the utility of qualitative MRI imaging in monitoring bone marrow volume as an index of disease severity, which may be useful in monitoring the efficacy of treatments for sickle cell disease and other chronic anemias.
44. Liao JH, Jara H, Nadgir R, et al. qMRI relaxometry of mandibular bone marrow: a monomodal distribution in sickle cell disease. J Magn Reson Imaging 2013; 37:1182-1188. This study describes a monomodal distribution of T1 and T2 quantitative MRI histograms of mandibular bone in sickle cell disease that confirms the persistence of red marrow in the mandible compared to controls.
45. Issa K, Naziri Q, Maheshwari AV, et al. Excellent results and minimal complications of total hip arthroplasty in sickle cell hemoglobinopathy at mid-term follow-up using cementless prosthetic components. J Arthroplasty 2013; 28:1693-1698. This is a sentinel study that challenges the historical dogma that discouraged total hip arthroplasty as early treatment for symptomatic advanced osteonecrosis in sickle cell disease. It clearly demonstrates similar longevity and low complication rates for THA in both sickle cell and nonsickle cell patient groups with the use of cementless prosthesis and comprehensive medical management.
46. Poignard A, Flouzat-Lachaniette CH, Amzallag J, et al. The natural progression of symptomatic humeral head osteonecrosis in adults with sickle cell disease. J Bone Joint Surg Am 2012; 94:156-162. The epidemiology and natural history of humeral head osteonecrosis is described as similar to that of femoral head osteonecrosis in sickle cell disease.
47. Marti-Carvajal AJ, Sola I, Agreda-Perez LH. Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database Syst Rev 2012; 5:CD004344. This comprehensive review of the literature reveals the lack of newer randomized studies on effective treatments for osteonecrosis in sickle cell disease in nearly a decade.
48. Neumayr L, Aguilar C, Earles A, et al. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease: results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am 2006; 88:2573-2582.
49. Hanker GJ, Amstutz HC. Osteonecrosis of the hip in the sickle-cell diseases. Treatment and complications. J Bone Joint Surg Am 1988; 70:499-506.
50. Bishop AR, Roberson JR, Eckman JR, Fleming LL. Total hip arthroplasty in patients who have sickle-cell hemoglobinopathy. J Bone Joint Surg Am 1988; 70:853-855.
51. Clarke HJ, Jinnah RH, Brooker AF, Michaelson JD. Total replacement of the hip for avascular necrosis in sickle cell disease. J Bone Joint Surg Br 1989; 71:465-470.
52. Acurio MT, Friedman RJ. Hip arthroplasty in patients with sickle-cell haemoglobinopathy. J Bone Joint Surg Br 1992; 74:367-371.
53. Moran MC, Huo MH, Garvin KL, et al. Total hip arthroplasty in sickle cell hemoglobinopathy. Clin Orthop Relat Res 1993; 140-148.
54. Sanjay BK, Moreau PG. Bipolar hip replacement in sickle cell disease. Int Orthop 1996; 20:222-226.
55. Hickman JM, Lachiewicz PF. Results and complications of total hip arthroplasties in patients with sickle-cell hemoglobinopathies. Role of cementless components. J Arthroplasty 1997; 12:420-425.
56. Al-Mousawi FR, Malki AA. Managing femoral head osteonecrosis in patients with sickle cell disease. Surgeon 2007; 5:282-289.
57. Ilyas I, Moreau P. Simultaneous bilateral total hip arthroplasty in sickle cell disease. J Arthroplasty 2002; 17:441-445.
58. Hernigou P, Zilber S, Filippini P, et al. Total THA in adult osteonecrosis related to sickle cell disease. Clin Orthop Relat Res 2008; 466:300-308.
59. Baldwin C, Nolan V, Wyszynski D, et al. Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis. Blood 2005; 106:372-375.
60. Pandey S, Ranjan R,Mishra RM, et al. Effect of ANXA2 gene single nucleotide polymorphism(SNP) on the development of osteonecrosis in Indian sickle cell patient: a PCR-RFLP approach. Indian J Exp Biol 2012; 50:455-458. This study supports the investigation of gene polymorphisms of the ANXA2 gene as a predictive biomarker of osteonecrosis in sickle cell disease.
61. Jain R, Sawhney S, Rizvi SG. Acute bone crises in sickle cell disease: the T1 fat-saturated sequence in differentiation of acute bone infarcts from acute osteomyelitis. Clin Radiol 2008; 63:59-70.
62. Inusa BP, Oyewo A, Brokke F, et al. Dilemma in differentiating between acute osteomyelitis and bone infarction in children with sickle cell disease: the role of ultrasound. PLoS One 2013; 8:e65001. This study suggests that the use of ultrasound in combination with total white cell count and mean C-reactive protein is a reliable and cost-effective tool to differentiate between the diagnosis of acute osteomyelitis and bone infarcts in sickle cell disease.
63. Solav SV, Bhandari R, Solav P. Skeletal scintigraphy manifestations of hematologic disorders. Indian J Nucl Med 2012; 27:59-62. Solav et al. suggests the continued utility of bone scintigraphy in the early diagnosis of skeletal manifestations of hematological disorders when used in conjunction with detailed history and clinical presentation.